Boundless Bio, Inc. (BOLD) Stock Forecast
BOLD analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 1 analysts
- Price target
- $4.00 average of analyst targets
- Upside to target
- +70.9% from the latest close
- Next earnings
- November 4, 2026
- 52-week range
- $1.05 – $3.00
BOLD analyst ratings
1 analystsNumber of analysts at each rating.
BOLD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BOLD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.56 | −$0.56 | −$0.62 | +9.7% | 1 |
| Current fiscal year (2026) | −$2.53 | −$2.53 | −$2.53 | −$2.60 | +2.7% | 1 |
| Next fiscal year (2027) | −$0.98 | −$0.98 | −$0.98 | −$2.53 | +61.3% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BOLD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
BOLD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BOLD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.64 | −$0.63 | −$0.61 | −$0.61 | −$0.56 | −12.5% | 0 up · 1 down |
| Current fiscal year (2026) | −$2.33 | −$2.38 | −$2.40 | −$2.40 | −$2.53 | +8.4% | 1 up · 1 down |
| Next fiscal year (2027) | −$1.28 | −$1.28 | −$0.93 | −$0.93 | −$0.98 | −23.4% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BOLD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BOLD beat in 6 of 12.
What analysts expect from BOLD
1 analysts cover Boundless Bio; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.00, 70.9% above the latest close of $2.34. Analysts expect earnings of −$2.53 per share for 2026, +2.7% from a year earlier. For 2027 the average estimate is −$0.98 per share. Boundless Bio beat the EPS estimate in 6 of the last 12 quarters.
Related: BOLD income statement, BOLD key metrics, BOLD chart. See the BOLD stock overview for the latest quote and news.
BOLD forecast FAQ
What is Boundless Bio's price target?
The average analyst price target for Boundless Bio is $4.00, 70.9% above the latest close of $2.34.
Is Boundless Bio a buy, hold or sell?
Of 1 analysts covering Boundless Bio, 0 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Boundless Bio's EPS forecast?
Analysts forecast −$2.53 per share for 2026 (range −$2.53 to −$2.53); for 2027 the estimate is −$0.98.
When does Boundless Bio report earnings?
Boundless Bio is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
Does Boundless Bio usually beat earnings estimates?
Boundless Bio reported EPS at or above the analyst estimate in 6 of the last 12 quarters.